TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00901654

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE527 vaccine
Description: First cohort: Two doses, each of 3x10\^9 cfu of each strain (9x10\^9 cfu total per dose) administered on Days 0 and Day 21 (out-patient).~Second cohort: Two doses, each of 3x10\^10 cfu of each strain (9x10\^10 cfu total per dose) administered on Days 0 and Day 21

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaccine
Description: First and second cohort: The placebo vaccine will be administered at Days 0 and Days 21.
Study: NCT00269360

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic + Supervised Rehabilitative Exercise
Description: Chiropractic care will include manual spinal manipulation, with light soft tissue massage as indicated to facilitate the spinal manipulative therapy. The spinal levels treated will be determined by the individual chiropractors by static and/or motion palpation.~Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supervised Rehabilitative Exercise
Description: Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care education
Description: Self-care education will be provided by the therapist trained in the study protocol. Two, one-hour sessions will be given regarding self-care measures and ergonomics relative to work and activities of daily living. These will include postural instructions and practical demonstrations of proper body mechanics performed with patient participation.
Study: NCT00090129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onercept
Description: Onercept will be administered subcutaneously three times a week at a dose of 150 mg, for 12 weeks of first treatment (FT) period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment or until relapse, whichever occurs first. Subjects then will be reassigned to either Onercept (150 mg) or placebo, subcutaneously three times a week, for 16 weeks. Subjects not showing 75 percent improvement in PASI score at Week 12 will receive only Onercept (150 mg) subcutaneously three times a week, for 40 weeks as open-label treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo will be administered subcutaneously three times a week, for 12 weeks in the FT period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment and then again assigned to either placebo or Onercept (150 mg), subcutaneously three times a week, for 16 weeks.
Study: NCT03730480

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour Next and Contour TV3 BGMS testing by subjects with and without Diabetes
Description: Using the first blood glucose monitoring system (BGMS), which is either Contour Next or Contour TV3, subjects perform self fingerstick test and alternative site test on the palm. Staff performs fingerstick test on subject. Using the second BGMS, the palm, self test and staff tests are performed. Subjects with diabetes get a venipuncture and staff tests using both BGMS using the venous blood.
Study: NCT02880345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEMBROLIZUMAB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEMBROLIZUMAB

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: hypofractionated radiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: hypofractionated radiation
Study: NCT01248780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: 50 mg subcutaneous (SC) injection every 4 weeks for up to 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter up to Week 48.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Description: A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
Study: NCT01953653

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Structured daily diary
Description: The intervention is a structured daily diary to describe fluctuations in key psychological and behavioral variables impacting daily risk behavior among HIV-positive young men who have sex with men (YMSM), aged 16 to 24 years old who engage in substance use and sexual risk behaviors.
Study: NCT04526730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavo
Description: Tavo will be injected on Days 1 and 8 every 4 weeks at a dose volume of ¼ of the calculated lesion volume with a minimum dose volume per lesion of 0.1 mL for lesions of volume \<0.4 cm3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered 480 mg every 4 weeks over 30 minute infusions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncoSec Medical Electroporation Therapy System
Description: The OMS (OncoSec Medical Electroporation Therapy System), a medical EP device system, consists of 3 components: 1. an Electroporation Generator that generates electric pulses, 2. a sterile Applicator Tip containing needle array, and 3. an Applicator Handle that connects to the Electroporation Generator at the proximal end and connects to the Applicator Tip at the distal end.~Upon user activation of the attached Foot Switch, the OMS Electroporation Generator delivers controlled electrical pulses in a square wave pulse pattern yielding optimal transmembrane potential for electroporation to occur. EP pulses occur between 6 hexagonal opposing needle electrodes. After the first pulse, the polarity between the opposing needle electrode pairs is reversed and the needle pair is pulsed again. After the initial paired pulse, the pulse delivery is rotated clockwise to the next opposing needle pairs until a total of 6 pulses are delivered to complete the EP sequence.
Study: NCT02514135

Intervention type: OTHER
Intervention: No intervention

Intervention type: OTHER
Intervention: No intervention
Study: NCT00742612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARC1779 Injection
Description: Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The ARC1779 treatment group will be dosed to achieve a target ARC1779 steady-state plasma concentration of 3 Ug/mL, using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
Study: NCT00742612

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The placebo group will be dosed to a steady-state plasma concentration using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
Study: NCT02699086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-1421 Capsule
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDC-1421 Capsule
Description: PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.
Study: NCT05035784

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fecal supernatant
Description: Fecal supernatant from a child registered in the specimen bank that matches the subject's age, gender, and weight .

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a placebo designed to match the FMT+RCE group based on appearance including 0.9% physiological saline.
Study: NCT01227577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules.
Study: NCT01670955

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Jobelyn
Description: Jobelyn is a sorghum bicolor extract marketed as dietary supplement

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulphate + Folic Acid
Description: Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulphate + Folic Acid
Description: Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
Study: NCT02896049

Intervention type: DEVICE
Intervention: Hyperthermia
Description: treatment with the Celsius42 Hyperthermia System additional to radiotherapy and/or chemotherapy
Study: NCT04357197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop
Description: The system will be tested to see if it can avoid hypotension
Study: NCT01159587

Intervention type: DRUG
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: Long-term secondary prophylaxis with product administered 20-30 UI /kg three times weekly

Intervention type: DRUG
Intervention: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Description: On-demand treatment with product given only for bleeding episodes
Study: NCT02335177

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interventional arm
Description: At home patients have both technologies for autonomy (walkers, treadmill) and tailored physical activity program performed with the help of the home carer. Intervention takes 3 months. Assessment at hospital discharge et at 3 months.
Study: NCT03241225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EM/PROTECT
Description: EM/PROTECT is a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EM/MH
Description: EM/MH provides individuals experiencing elder mistreatment with support services from staff trained in linking elder mistreatment victims to community mental health services.
Study: NCT01762319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin B6
Study: NCT03356626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ULTRACISION Harmonic Scalpel
Description: to use ULTRACISION Harmonic Scalpel when performing gastrectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ligasure Maryland
Description: to use Ligasure Maryland when performing gastrectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thunderbeat
Description: to use Thunderbeat when performing gastrectomy
Study: NCT03104868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAKE IT Strategy
Description: The TAKE IT Strategy includes:~1. Programming the electronic health record (EHR) to organize/simplify daily regimen schedules and generate electronic, tangible, print, low literacy medication education materials at every clinical encounter.~2. SMS text-messaging to remind patients when to take all their medicine.~3. A web-based patient portal that requests patients to periodically report upon their medication use, providing a continuous link between the transplant center and patient beyond routine in-person visits.~4. EHR notifications directed to the transplant center nurse coordinator if an adherence-related problem is identified by the web-based portal assessment, who then can activate appropriate staff to respond.
Study: NCT05035537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PGDT
Description: The minimally invasive continuous CI monitor (Edwards ClearSight) was used to guide an optimization of preload with the use of algorithms based on fluids, inotropes and/or vasopressors to achieve a certain goal in medium arterial pressure (MAP), cardiac index (CI) and stroke volume variation (SVV)
Study: NCT01814111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal sympathetic denervation
Description: The ablation catheter was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis.
Study: NCT04500587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-d5
Description: Oral agent; 25 mg or 100 mg formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-d5
Description: Oral agent; 25 mg or 100 mg formulation
Study: NCT02338674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir and telbivudine
Description: tenofovir and telbivudine administered at least 48 weeks
Study: NCT03756987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Injection
Description: Ropivacaine will be injected in the erector spinae plane
Study: NCT02338674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: tenofovir administered at least 48 weeks
Study: NCT00317980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meglumine antimoniate
Description: Meglumine antimoniate 5mg/kg/d for 20 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate
Description: Meglumine antimoniate 15 mg/kg/d for 20 days
Study: NCT02346123

Intervention type: GENETIC
Intervention: Gathering of samples of genetic material
Description: The samples will be obtained from peripheral blood mononuclear cells and the genotyping of the polymorphisms will be done by real time PCR.
Study: NCT03096808

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: ART involved modification of the radiation treatment plan during treatment course to account for temporal variations in anatomy due to changes in tumor volume and/or patients' weight loss.
Study: NCT01730599

Intervention type: OTHER
Intervention: neurological exam
Description: motor and cognitive functions
Study: NCT06294626

Intervention type: OTHER
Intervention: Group 1
Description: 21 cases with scaphocephaly diagnoses were included. Neuromotor development was evaluated with the Denver-II Developmental Screening Test and Alberta Infant Motor Scale.
Study: NCT04246788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive robotic rehabilitation
Description: 5 sessions per week of 30 minutes of robot-assisted rehabilitation with the G-EO system during two weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classical physiotherapy
Description: 3 sessions per week of 30 minutes of classical physiotherapy during two weeks
Study: NCT04440475

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP block
Description: Tap block description:~The skin is prepped and draped in a sterile fashion for a lateral to posterior/lateral approach to the Transverse Abdominis Plane (TAP). The Anesthesiologists use ultrasound guidance for all TAP blocks and pre mix 60cc of 0.2% ropivicaine with 10mg of preservative free dexamethasone. After the plane is identified in approximately the mid axillary line, a 17g Tuohy needle is used under ultrasound guidance to enter the potential space from an anterior approach. The needle is visualized in-plane with the ultrasound probe, traversing the exterior and interior oblique muscles and penetrating through the posterior fascia of internal oblique into the transverse abdominal plane. Once the Tuohy is in place, the needle is aspirated and the plane is hydro-dissected using 0.2% Ropivicaine with 10mg of dexamethasone. The anesthesiologist will use 30ml of 0.2% Ropivicaine on each side.
Study: NCT01128933

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal artery stenting
Study: NCT03532451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 480 mg intravenously (IV) over approximately 30 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab/Lirilumab
Description: Nivolumab 480 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) with at least a 30 minute rest between infusions followed by lirilumab 240 mg IV over approximately 60 minutes every 4 weeks for 2 neo-adjuvant doses (week 0 and 4) followed by RC with bilateral (standard or extended) PLND as soon as possible but within 6 weeks after the last neoadjuvant infusion.
Study: NCT02375854

Intervention type: OTHER
Intervention: Observation
Study: NCT04421677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylbutyrate Oral Tablet
Description: Phenylbutyrate, an orally active chemical chaperone approved by the US Food and Drug Administration for treatment of urea cycle disorders, mimics the function of intracellular molecular chaperones in preventing protein aggregation and oligomerization.
Study: NCT05225090

Intervention type: OTHER
Group type: OTHER
Intervention: Smartphone App
Description: Medisafe is a Med_App that is free and has been used in several studies evaluating medication adherence. Patients will receive individualized instruction and be followed for 12 weeks. The researcher will show the patients how to input current medication list, set up medication reminders and track if daily doses have been taken using the App (20 minute training session). After the participant has input their medication information into the app, the researcher will assist the participant in adding an optional Medifriend who will be alerted if the participant misses a dose as an option. The participant will also be provided with written instructions about the Medisafe app to take home for reference. At each office visit (4, 8, and 12 weeks) participants will complete a medication checklist and reconciliation form with the research staff. Participants will also be asked to send a medication status report through the Medisafe app.
Study: NCT03021200

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green indocianine
Description: Laser fluorescence using green indocianine guiding the surgical procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green indocianine
Description: Laser fluorescence using green indocianine guiding the surgical procedure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green indocianine
Description: Laser fluorescence using green indocianine guiding the surgical procedure.
Study: NCT03373240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU plus Cognitive Remediation Program
Description: Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS computerized games that focus on cognitive-affective self-regulatory processes.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TAU plus Control Tasks
Description: Treatment normally received at this clinic that generally includes individual or group sessions and regular urine monitoring PLUS a series of computerized word games.
Study: NCT04440033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baseline assessment of demographic, anthropometric and clinical characteristics
Description: * Age~* Sex~* Height~* Body weight~* Handedness~* Medication use~* Blood pressure~* Global cognition (Montreal Cognitive Assessment)~* Fear of falling (Shortened Iconographical Falls Efficacy Scale)~* History of falls (number of falls in the past month)~* Time since diagnosis and symptom onset~* Disease severity (UPDRS part III, Hoehn and Yahr)~* Non-motor symptoms (UPDRS part I)~* Motor symptoms (UPDRS part III)~* Motor complications (UPDRS part IV)~* Disease-dominant side (UPDRS part III)~* Freezing of gait (New Freezing of Gait Questionnaire)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline assessment of demographic, anthropometric and clinical characteristics
Description: * Age~* Sex~* Height~* Body weight~* Handedness~* Medication use~* Blood pressure~* Global cognition (Montreal Cognitive Assessment)~* Fear of falling (Shortened Iconographical Falls Efficacy Scale)~* History of falls (number of falls in the past month)
Study: NCT03756987

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will be injected in the erector spinae plane.
Study: NCT02819362

Intervention type: DEVICE
Intervention: MRI
Description: The magnetic resonance imaging (MRI) will be performed before the two-step surgery: a ductal-MRI sequence (highly weighted sagittal T2) - followed by sequence with axial plane, T2, T1, injection in dynamic sequences, subtractions.
Study: NCT01952353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoprative TACE
Study: NCT03844347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management sessions
Description: Stress management sessions are proposed to the patients and consist of small exercises focused on breathing and bodily sensations. Each accompanying person has access to different exercises. The sessions are adapted to the state of the patient to promote his well-being, before or after his/her operation. The duration of a preoperative session is 1 hour, the duration of the postoperative sessions is 15 minutes.
Study: NCT04444076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REGENETEN Bioinductive Implant
Description: REGENETEN bioinductive Implant,a reconstituted bovine origin type I collagen mesh with a proprietary high porosity system that is commercialized sterile, dehydrated and desiccated in two sizes (20x26mm and 25x31mm). It will be implanted following supraspinatus tendon repair.
Study: NCT04583618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine - formulation 1-SP0202-IIb
Description: Pharmaceutical form:Suspension for injection Route of administration: intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Conjugate Vaccine - formulation 2-SP0202-VI
Description: Pharmaceutical form:Suspension for injection Route of administration: intramuscular